Galectin Therapeutics Inc.
Galectin Therapeutics Inc. (GALT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
galt · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Galectin Therapeutics Inc. (GALT) measures how much investors pay for each dollar of the company's trailing earnings. GALT's current PE ratio of N/A is calculated by dividing its stock price of $2.36 by its TTM earnings per share of -$0.40.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Galectin Therapeutics Inc.You GALT | $155M | N/A | — | -$0.40 |
 Altimmune, Inc. ALT | $240M | N/A | — | -$1.00 |
 Aura Biosciences, Inc. AURA | $417M | N/A | — | -$1.76 |
 DiaMedica Therapeutics Inc. DMAC | $299M | N/A | — | -$0.70 |
 Alpha Tau Medical Ltd. DRTS | $843M | N/A | — | -$0.53 |
 Design Therapeutics, Inc. DSGN | $656M | N/A | — | -$1.22 |
 enGene Holdings Inc. ENGN | $84M | N/A | — | -$2.29 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.48 | — | |
2024-12-31 FY2024 | — | $-0.76 | — | |
2023-12-31 FY2023 | — | $-0.68 | — | |
2022-12-31 FY2022 | — | $-0.65 | — | |
2021-12-31 FY2021 | — | $-0.52 | — | |
2020-12-31 FY2020 | — | $-0.41 | — | |
2019-12-31 FY2019 | — | $-0.25 | — | |
2018-12-31 FY2018 | — | $-0.35 | — | |
2017-12-31 FY2017 | — | $-0.46 | — | |
2016-12-31 FY2016 | — | $-0.73 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Galectin Therapeutics Inc. (GALT) measures how much investors pay for each dollar of the company's trailing earnings. GALT's current PE ratio of N/A is calculated by dividing its stock price of $2.36 by its TTM earnings per share of -$0.40.
Frequently asked questions
GALT pe ratio · 6 questionsGALT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.36 and TTM EPS of -$0.40. Data sourced from Financial Modeling Prep via GALT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Galectin Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08